{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:55:57Z","timestamp":1795085757351,"version":"4.10.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural funding University of Ulm"},{"name":"EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox","award":["01ED2008A"],"award-info":[{"award-number":["01ED2008A"]}]},{"name":"German Federal Ministry of Education and Research","award":["FTLDc 01GI1007A"],"award-info":[{"award-number":["FTLDc 01GI1007A"]}]},{"name":"EU (Moodmarker) program","award":["01EW2008"],"award-info":[{"award-number":["01EW2008"]}]},{"name":"German Research Foundation\/DFG","award":["SFB1279"],"award-info":[{"award-number":["SFB1279"]}]},{"name":"Foundation of the state Baden-W\u00fcrttemberg","award":["D.3830"],"award-info":[{"award-number":["D.3830"]}]},{"name":"Boehringer Ingelheim Ulm University BioCenter","award":["D.5009"],"award-info":[{"award-number":["D.5009"]}]},{"name":"Thierry Latran Foundation","award":["D.2468"],"award-info":[{"award-number":["D.2468"]}]},{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer\u2019s disease (AD). However, studies investigating the differential diagnostic potential in cerebrospinal fluid (CSF) are rare and are not available for blood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We set up a novel, sensitive single molecule array (Simoa) assay for the detection of VILIP-1 in CSF and serum. In total, paired CSF and serum samples from 234 patients were investigated: 73 AD, 18 behavioral variant frontotemporal dementia (bvFTD), 26 parkinsonian syndromes, 20 amyotrophic lateral sclerosis (ALS), 22 Creutzfeldt-Jakob disease (CJD), and 75 non-neurodegenerative control (Con) patients. The differential diagnostic potential of CSF and serum VILIP-1 was assessed using the receiver operating characteristic curve analysis and findings were compared to core AD biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CSF and serum VILIP-1 levels correlated weakly (<jats:italic>r<\/jats:italic>=0.32 (CI: 0.20\u20130.43), <jats:italic>p<\/jats:italic>&lt;0.0001). VILIP-1 concentrations in CSF and serum were elevated in AD compared to Con (<jats:italic>p<\/jats:italic>&lt;0.0001 and <jats:italic>p<\/jats:italic>&lt;0.01) and CJD (<jats:italic>p<\/jats:italic>&lt;0.0001 for CSF and serum), and an increase in CSF was observed already in early AD stages (<jats:italic>p<\/jats:italic>&lt;0.0001). In the discrimination of AD versus Con, we could demonstrate a strong diagnostic potential for CSF VILIP-1 alone (area under the curve (AUC): 0.87), CSF VILIP-1\/CSF Abeta 1-42 (AUC: 0.98), and serum VILIP-1\/CSF Abeta 1-42 ratio (AUC: 0.89).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We here report on the successful establishment of a novel Simoa assay for VILIP-1 and illustrate the potential of CSF and serum VILIP-1 in the differential diagnosis of AD with highest levels in CJD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01122-4","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:13:11Z","timestamp":1669180391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer\u2019s and other neurodegenerative diseases"],"prefix":"10.1186","volume":"14","author":[{"given":"Steffen","family":"Halbgebauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anderl-Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolina","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A. F.","family":"von Arnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Nagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"6","key":"1122_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"key":"1122_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","volume":"5","author":"D Galasko","year":"2019","unstructured":"Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2019;5:871\u201382.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1122_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res. 2010;1362:13\u201322.","journal-title":"Brain Res"},{"key":"1122_CR4","doi-asserted-by":"publisher","unstructured":"Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, Froelich L, Gomes LA, Hausner L, Huss A, Jahn H, Weishaupt J, Ludolph AC, Thal DR, Otto M. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2021;92(4):349\u201356. https:\/\/doi.org\/10.1136\/jnnp-2020-324306. Epub 2020 Dec 30.","DOI":"10.1136\/jnnp-2020-324306"},{"key":"1122_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"MR Bronzuoli","year":"2016","unstructured":"Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res. 2016;9:199\u2013208.","journal-title":"J Inflamm Res"},{"issue":"2","key":"1122_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1122_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12017-016-8439-1","volume":"19","author":"P Shahim","year":"2017","unstructured":"Shahim P, Blennow K, Johansson P, Svensson J, Lista S, Hampel H, et al. Cerebrospinal fluid stanniocalcin-1 as a biomarker for Alzheimer\u2019s disease and other neurodegenerative disorders. NeuroMolecular Med. 2017;19(1):154\u201360.","journal-title":"NeuroMolecular Med"},{"issue":"1","key":"1122_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A Ohrfelt","year":"2016","unstructured":"Ohrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):41.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1122_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00441-008-0716-3","volume":"335","author":"KH Braunewell","year":"2009","unstructured":"Braunewell KH, Klein-Szanto AJ. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+-sensor proteins. Cell Tissue Res. 2009;335(2):301\u201316.","journal-title":"Cell Tissue Res"},{"issue":"8","key":"1122_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1007056731551","volume":"28","author":"HG Bernstein","year":"1999","unstructured":"Bernstein HG, Baumann B, Danos P, Diekmann S, Bogerts B, Gundelfinger ED, et al. Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J Neurocytol. 1999;28(8):655\u201362.","journal-title":"J Neurocytol"},{"key":"1122_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2012.00020","volume":"5","author":"KH Braunewell","year":"2012","unstructured":"Braunewell KH. The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer\u2019s disease-old wine in new bottles. Front Mol Neurosci. 2012;5:20.","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"1122_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1567205043332234","volume":"1","author":"M Kawahara","year":"2004","unstructured":"Kawahara M. Disruption of calcium homeostasis in the pathogenesis of Alzheimer\u2019s disease and other conformational diseases. Curr Alzheimer Res. 2004;1(2):87\u201395.","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"1122_CR13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrn960","volume":"3","author":"FM LaFerla","year":"2002","unstructured":"LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer\u2019s disease. Nat Rev Neurosci. 2002;3(11):862\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"1122_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fnmol.2013.00029","volume":"6","author":"E Popugaeva","year":"2013","unstructured":"Popugaeva E, Bezprozvanny I. Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease. Front Mol Neurosci. 2013;6:29.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"1122_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-150060","volume":"47","author":"M Groblewska","year":"2015","unstructured":"Groblewska M, Muszynski P, Wojtulewska-Supron A, Kulczynska-Przybik A, Mroczko B. The role of visinin-like protein-1 in the pathophysiology of Alzheimer\u2019s disease. J Alzheimers Dis. 2015;47(1):17\u201332.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1122_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5507\/bp.2011.049","volume":"155","author":"D Stejskal","year":"2011","unstructured":"Stejskal D, Sporova L, Svestak M, Karpisek M. Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2011;155(3):263\u20138.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia"},{"issue":"9","key":"1122_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1373\/clinchem.2006.070912","volume":"52","author":"OF Laterza","year":"2006","unstructured":"Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM, et al. Identification of novel brain biomarkers. Clin Chem. 2006;52(9):1713\u201321.","journal-title":"Clin Chem"},{"issue":"10","key":"1122_CR18","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00018-019-03040-5","volume":"76","author":"K Dhiman","year":"2019","unstructured":"Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer\u2019s disease pathogenesis. Cell Mol Life Sci. 2019;76(10):1833\u201363.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1122_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3233\/JAD-150705","volume":"50","author":"M Babic Leko","year":"2016","unstructured":"Babic Leko M, Borovecki F, Dejanovic N, Hof PR, Simic G. Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer\u2019s disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimers Dis. 2016;50(3):765\u201378.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1122_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.22448","volume":"70","author":"R Tarawneh","year":"2011","unstructured":"Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274\u201385.","journal-title":"Ann Neurol"},{"key":"1122_CR21","doi-asserted-by":"publisher","unstructured":"Dulewicz M, Kulczy\u0144ska-Przybik A, Mroczko B. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020;21(21):8335. https:\/\/doi.org\/10.3390\/ijms21218335.","DOI":"10.3390\/ijms21218335"},{"issue":"5","key":"1122_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","volume":"15","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease. Alzheimers Dementia. 2019;15(5):655\u201365.","journal-title":"Alzheimers Dementia"},{"issue":"Pt 9","key":"1122_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain J Neurol. 2011;134(Pt 9):2456\u201377.","journal-title":"Brain J Neurol"},{"issue":"5","key":"1122_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","volume":"24","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375\u201398.","journal-title":"CNS Drugs"},{"issue":"3","key":"1122_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1122_CR26","unstructured":"Brown P, Brunk C, Budka H, Cervenakova L, Collie D, Green A, Ronside J, Knight R, MacKenzie J, Pergami P, Ricketts M, Summers D, Will B, Zeidler M, Zerr I. WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. World Health Organization, Communicable Disease Surveillance and Response. 2003."},{"issue":"5","key":"1122_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"1122_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry J Ment Sci. 1982;140:566\u201372.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"8","key":"1122_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol. 2008;65(8):1091\u20135.","journal-title":"Arch Neurol"},{"issue":"6","key":"1122_CR30","first-page":"746","volume":"67","author":"SE O'Bryant","year":"2010","unstructured":"O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W, Khodr ZG, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer\u2019s coordinating center database. Arch Neurol. 2010;67(6):746\u20139.","journal-title":"Arch Neurol"},{"issue":"3","key":"1122_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349\u201356.","journal-title":"Mov Disord"},{"key":"1122_CR32","doi-asserted-by":"publisher","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE. A Practical Guide to Immunoassay Method Validation. Front Neurol. 2015;6:179. https:\/\/doi.org\/10.3389\/fneur.2015.00179.","DOI":"10.3389\/fneur.2015.00179"},{"issue":"10","key":"1122_CR33","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"JM Lee","year":"2008","unstructured":"Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54(10):1617\u201323.","journal-title":"Clin Chem"},{"issue":"10","key":"1122_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","volume":"78","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78(10):709\u201319.","journal-title":"Neurology."},{"issue":"5","key":"1122_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jnc.12331","volume":"127","author":"X Luo","year":"2013","unstructured":"Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurochem. 2013;127(5):681\u201390.","journal-title":"J Neurochem"},{"issue":"1","key":"1122_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbrc.2004.08.055","volume":"323","author":"P Gierke","year":"2004","unstructured":"Gierke P, Zhao C, Brackmann M, Linke B, Heinemann U, Braunewell KH. Expression analysis of members of the neuronal calcium sensor protein family: combining bioinformatics and Western blot analysis. Biochem Biophys Res Commun. 2004;323(1):38\u201343.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1122_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/JAD-2011-101959","volume":"25","author":"S Chalbot","year":"2011","unstructured":"Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, et al. Blood-cerebrospinal fluid barrier permeability in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;25(3):505\u201315.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1122_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00002093-199706000-00004","volume":"11","author":"H Hampel","year":"1997","unstructured":"Hampel H, Kotter HU, Moller HJ. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis Assoc Disord. 1997;11(2):78\u201387.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"1122_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-016-0225-7","volume":"8","author":"L Song","year":"2016","unstructured":"Song L, Lachno DR, Hanlon D, Shepro A, Jeromin A, Gemani D, et al. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-beta 1-42 peptide in human plasma with utility for studies of Alzheimer\u2019s disease therapeutics. Alzheimers Res Ther. 2016;8(1):58.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1122_CR40","doi-asserted-by":"publisher","first-page":"eaav1388","DOI":"10.1126\/sciadv.aav1388","volume":"5","author":"Y Kim","year":"2019","unstructured":"Kim Y, Yoo YK, Kim HY, Roh JH, Kim J, Baek S, et al. Comparative analyses of plasma amyloid-beta levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system. Sci Adv. 2019;5(4):eaav1388.","journal-title":"Sci Adv"},{"issue":"7691","key":"1122_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"issue":"10","key":"1122_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1122_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3233\/JAD-180409","volume":"66","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, Polischi B, Oppi F, Poda R, et al. Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J Alzheimers Dis. 2018;66(2):551\u201363.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1122_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-018-0361-3","volume":"10","author":"RW Paterson","year":"2018","unstructured":"Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther. 2018;10(1):32.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1122_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60\u20137.","journal-title":"JAMA Neurol"},{"issue":"15","key":"1122_CR46","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1212\/WNL.0000000000006318","volume":"91","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Anderl-Straub S, Diehl-Schmid J, Semler E, Uttner I, von Arnim CAF, et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91(15):e1390\u2013e401.","journal-title":"Neurology."},{"issue":"2","key":"1122_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1122_CR48","first-page":"12","volume":"87","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87(1):12\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1122_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","volume":"79","author":"P Weydt","year":"2016","unstructured":"Weydt P, Oeckl P, Huss A, Muller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152\u20138.","journal-title":"Ann Neurol"},{"issue":"5","key":"1122_CR50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1006\/nbdi.2001.0432","volume":"8","author":"I Schnurra","year":"2001","unstructured":"Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer\u2019s disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer\u2019s disease? Neurobiol Dis. 2001;8(5):900\u20139.","journal-title":"Neurobiol Dis"},{"issue":"Suppl 1","key":"1122_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K. A review of fluid biomarkers for Alzheimer\u2019s disease: moving from CSF to blood. Neurol Ther. 2017;6(Suppl 1):15\u201324.","journal-title":"Neurol Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01122-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:19:23Z","timestamp":1669180763000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01122-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01122-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All CSF and serum specimens examined in this study were from patients seen in the Departments of Neurology Ulm (between 2010 and 2020) and G\u00f6ttingen (1997\u20132003). The study was approved by local Ethics Committees (approval numbers: Ulm 20\/10, G\u00f6ttingen 100305) and conducted following the Declaration of Helsinki. All participants gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SH, PS, DR, PO, ML, SAS, JL, AG, and ACL have nothing to report. CFA received honoraria from serving on the scientific advisory board of Biogen, Roche, and Dr. Willmar Schwabe GmbH & Co. KG and has received funding for travel and speaker honoraria from Lilly GmbH, Daiichi Sankyo, Biogen, Roche diagnostics AG, and Dr. Willmar Schwabe GmbH & Co. KG and has received research support from Roche diagnostics AG. MO gave scientific advice for Fujirebio, Roche, Biogen, and Axon.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}